Does Insurance Cover Zepbound? The Answer Isn't Your Insurer

The most common version of this question names an insurer: does Blue Cross Blue Shield cover Zepbound, does UnitedHealthcare cover Wegovy, does Cigna cover tirzepatide. Every one of them has the same answer, and it is not a dodge: the name on your card does not determine whether the drug is covered.

That sounds like an evasion until you see what actually decides it. Then it becomes the most useful thing anyone can tell you, because it redirects you from a question with no answer to one you can settle in about ten minutes.

Blue Cross Blue Shield is not a company

Blue Cross Blue Shield is an association of 33 independent, locally operated companies — Anthem Blue Cross, Blue Cross Blue Shield of Michigan, Highmark, Elevance, Premera and so on. They share a brand and a network agreement. They do not share a formulary.

So "does BCBS cover Zepbound" is roughly like asking whether franchised restaurants serve a particular dish. Some do. The one nearest you is the only one whose answer matters, and it is not bound by what the others decided.

UnitedHealthcare, Aetna and Cigna are single companies, so this particular problem does not apply to them. The next one does, and it is bigger.

For employer coverage, your employer decides — not the insurer

This is the part almost nobody explains, and it accounts for most of the confusion.

Most large employers self-fund their health plans. In a self-funded arrangement the employer pays claims out of its own assets and hires an insurance company to administer the plan — process claims, run the network, print the cards. UnitedHealthcare's name is on your card because UnitedHealthcare is administering your employer's plan, not because UnitedHealthcare is insuring you.

In that arrangement, benefit design is the employer's decision. Whether anti-obesity medications are covered at all is a line item your employer chose to buy or not to buy, usually as a rider with a substantial price attached. GLP-1 medications are expensive enough that a great many employers have specifically excluded them, and a number that once covered them have since dropped the benefit.

The consequence is concrete: two people holding identical UnitedHealthcare cards, seeing the same doctor, with the same BMI and the same prescription, can get opposite answers — because they work for different companies. Neither insurer nor doctor did anything different.

This is also why calling the insurer's general line often produces a vague response. The representative can read your plan's terms, but the plan's terms were written by your employer.

The three things that actually decide it

Once you stop asking about the brand, the question resolves into three checks, in this order.

1. Is the drug on your plan's formulary at all?

The formulary is your specific plan's list of covered drugs and their tiers. It is not the insurer's list — it is your plan's, and your plan is identified by the group number on your card. If anti-obesity medications are excluded as a category, no clinical argument will change that, because it is a contract term rather than a medical decision.

2. What is it being prescribed for?

This is where Zepbound differs from every weight-loss-only product, and it matters more than most people realise.

Zepbound holds FDA approval for moderate-to-severe obstructive sleep apnoea in adults with obesity, alongside its weight-management indication. That is a separate, non-weight-loss medical indication, and plans that exclude "weight loss drugs" as a category frequently do cover drugs for a diagnosed condition. The same logic already reshaped Medicare coverage, where a 2003 statute excludes weight-loss drugs but a qualifying non-weight indication is a different matter — see does Medicare cover GLP-1 and Zepbound for sleep apnoea.

If you have diagnosed sleep apnoea, that diagnosis — properly documented — can be the difference between a denial and an approval on a plan that would never have covered the same drug for weight alone.

3. What does the prior authorisation require?

Almost every plan that covers a GLP-1 requires prior authorisation, and the criteria are where approvals are actually won and lost: a documented BMI threshold, often a comorbidity, sometimes a documented history of supervised weight-management attempts, and increasingly step therapy through a cheaper medication first. Our guidance is in prior authorisation tips and getting a GLP-1 covered.

How to get a real answer in ten minutes

1. Find your group number on your insurance card. This identifies your specific plan, which is what everything below depends on.
2. Open your plan's drug list, not the insurer's homepage. Log in to your member portal and look for "formulary", "prescription drug list" or "drug cost tool". Search for Zepbound by name. You are looking for three things: is it listed, what tier, and is prior authorisation flagged.
3. If it is not listed, search for Wegovy, Saxenda and Contrave too. A plan that excludes one anti-obesity drug usually excludes all of them, and confirming that saves you the appeal.
4. Call the pharmacy benefit number — the one on the back of your card, not the general line — and ask two specific questions: "Is Zepbound on my plan's formulary?" and "Does my plan cover anti-obesity medications, or is that category excluded?" The second question is the one that actually settles it.
5. If you have sleep apnoea, ask separately whether Zepbound is covered for the obstructive sleep apnoea indication. Some plans answer that differently from the weight question, and the representative will not volunteer it.

For plans administered through a pharmacy benefit manager, the drug list may live with the PBM rather than the insurer — CVS Caremark, Express Scripts and Optum Rx are the three large ones, and the name is usually printed on the card.

Government coverage is a different question

Medicare, Medicaid and TRICARE do not work like commercial plans, and each has its own rules rather than an employer's choices:

• Medicare: a 2003 statute excludes drugs used for weight loss from Part D, but a qualifying non-weight indication changes the analysis. See our Medicare guide.
• Medicaid: coverage is decided state by state and varies enormously. See Medicaid coverage by state.
• TRICARE and VA: military and veteran coverage follows its own formulary process, and — importantly — enrolment in any government programme makes you ineligible for every manufacturer copay card, including Zepbound's.

If the answer is no

An exclusion is a contract term, so the routes that remain are not appeals:

• Self-pay through the manufacturer. Zepbound is available at $299 to $449 a month depending on dose, which for many people is less than the copay an uncovered plan would leave them with. The conditions attached — including a 45-day refill window on higher doses — are in the Zepbound savings card guide.
• A different medication your plan does cover. If cost is the binding constraint, a covered alternative can beat an uncovered first choice. See Wegovy versus Zepbound and the non-GLP-1 options.
• Raise it at open enrolment. If your employer offers more than one plan, the drug lists differ, and this is the one moment in the year when the answer is actually under your control.
• Compare the real numbers before assuming coverage is cheaper. See Zepbound cost per month and our GLP-1 cost index.

This article is educational and is not medical, legal or financial advice. Formularies, prior-authorisation criteria and employer benefit designs change frequently and vary by plan. Confirm current details with your plan, your pharmacy benefit manager and your prescriber.